Liver transplantation for primary sclerosing cholangitis

Area of Science:

• Hepatology
• Gastroenterology
• Transplant Surgery

Background:

• Primary sclerosing cholangitis (PSC) is a progressive, chronic cholestatic liver disease.
• Liver transplantation is the definitive treatment for end-stage liver disease due to PSC.
• PSC recurrence post-transplant is common but does not significantly impact patient survival.

Purpose of the Study:

• To evaluate the outcomes of liver transplantation for patients with primary sclerosing cholangitis.
• To assess the impact of PSC recurrence and cholangiocarcinoma on transplant outcomes.
• To review the management of associated inflammatory bowel disease (IBD) post-transplant.

Main Methods:

• Analysis of liver transplant outcomes in patients with PSC.
• Evaluation of survival rates based on pre-transplant factors (Child-Pugh stage).
• Assessment of PSC recurrence, cholangiocarcinoma presence, and IBD activity post-transplant.

Main Results:

• Excellent survival rates post-liver transplant for PSC (90-97% at 1 year, 80-85% at 5 years), correlated with pre-transplant Child-Pugh stage.
• PSC recurrence occurs in up to 20% of patients but has minimal impact on survival.
• Liver transplantation for microscopic cholangiocarcinoma shows similar survival to PSC without cancer; outcomes are poor for clinically apparent cholangiocarcinoma.
• Increased IBD activity and a 7% incidence of colon cancer post-transplant in IBD patients warrant consideration.

Conclusions:

• Liver transplantation offers excellent survival for PSC patients, with recurrence having little effect.
• Early detection of microscopic cholangiocarcinoma is crucial for favorable transplant outcomes.
• Close monitoring for IBD activity and colon cancer is recommended for PSC patients undergoing liver transplantation.